Skip to main content
. 2009 Jul 2;150(10):4502–4511. doi: 10.1210/en.2009-0445

Figure 1.

Figure 1

ARC-directed leptin receptor gene therapy improves insulin sensitivity via increased suppression of endogenous glucose production. Arterial glucose (A) and GIR (B) required to maintain euglycemia during the euglycemic-hyperinsulinemic clamp in obese Koletsky rats that received Ad-GFP or Ad-LEPR-B directed to the ARC. Rd (C) and the endogenous rate of glucose appearance (Endo Ra) (D) in Ad-GFP- and Ad-LEPR-B-treated animals during the basal (open squares) and clamp (closed squares) period. Effect of ARC-directed leptin receptor gene therapy on percent increase in glucose uptake or disposal (E), percent suppression of hepatic glucose production (F), and hepatic mRNA levels of the gluconeogenic genes G6Pase (G) and Pepck (H) (n = 5/group). *, P < 0.05 vs. Ad-GFP.